Requip


Also found in: Dictionary.
Related to Requip: Restless Leg Syndrome, Requip XL

ropinirole hydrochloride

Adartrel (UK), Requip, Requip XL

Pharmacologic class: Dopamine agonist

Therapeutic class: Antidyskinetic

Pregnancy risk category C

Action

Unknown. Thought to stimulate dopamine receptors in brain.

Availability

Tablets: 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg

Tablets (extended-release): 2 mg, 4 mg, 6 mg, 8 mg

Indications and dosages

Idiopathic Parkinson's disease

Adults: For conventional tablets, initially, 0.25 mg P.O. t.i.d. for 1 week, followed by 0.5 mg P.O. t.i.d. for 1 week, then 0.75 mg t.i.d. for 1 week, and then 1 mg t.i.d. for 1 week. After week 4, may increase by 1.5 mg/day q week, up to 9 mg/day; then may increase further by up to 3 mg/day q week, up to 24 mg/day. For extended-release tablets, initially 2 mg P.O. once daily for 1 to 2 weeks, followed by increases of 2 mg/day at 1-week or longer intervals as appropriate, depending on therapeutic response and tolerability, up to a recommended maximum dosage of 24 mg/day.

Moderate to severe primary restless leg syndrome

Adults: Initially, 0.25 mg P.O. once daily, 1 to 3 hours before bedtime. After 2 days, may increase dosage to 0.5 mg once daily and to 1 mg once daily during week 2. For weeks 3 through 6, may increase dosage by 0.5 mg/week, to a dosage of 3 mg; at week 7, dosage may be increased to 4 mg (immediate-release tablets only).

Contraindications

• Hypersensitivity to drug or its components

Precautions

Use cautiously in:

• severe hepatic impairment or cardiovascular disease, bradycardia

• elderly patients

• pregnant patients

• breastfeeding patients (use not recommended).

Administration

• Give with food if drug causes nausea.

• Assess patient for therapeutic response and tolerability at 1-week intervals (minimum) or longer after each dosage increment.

• Know that drug withdrawal should occur over 7 days, with frequency reduced to twice-daily dosing for first 4 days and then to once-daily dosing for next 3 days.

Adverse reactions

CNS: headache, dizziness, confusion, drowsiness, fatigue, neuralgia, amnesia, hyperesthesia, yawning, dystonia, increased dyskinesia, hyperkinesia, akathisia, hallucinations, abnormal thinking, poor concentration, syncope, vertigo, myoclonus, asthenia, malaise, sleep attacks

CV: orthostatic hypotension, hypertension, palpitations, extrasystole, peripheral edema, peripheral ischemia, chest pain, tachycardia, atrial fibrillation

EENT: abnormal vision, rhinitis, sinusitis, pharyngitis

GI: nausea, vomiting, flatulence, abdominal pain, dyspepsia, dry mouth, anorexia

GU: urinary tract infection, decreased libido, erectile dysfunction

Respiratory: bronchitis, dyspnea

Skin: diaphoresis, flushing

Other: viral infection, pain, edema

Interactions

Drug-drug. Butyrophenones (such as haloperidol), metoclopramide, phenothiazines, thioxanthenes: decreased ropinirole effects

Ciprofloxacin, estrogens: increased ropinirole effects

Drugs that alter activity of CYP450-1A2 enzyme system: altered ropinirole clearance

Levodopa: increased levodopa effects

Drug-diagnostic tests. Alkaline phosphatase, blood urea nitrogen: increased levels

Drug-herbs. Kava: decreased ropinirole efficacy

Patient monitoring

• Monitor vital signs, especially for orthostatic hypotension. Assess for peripheral edema.

• Assess neurologic status carefully. Report severe adverse reactions.

• Monitor nutritional and hydration status.

Patient teaching

• Encourage patient to take drug with food if it causes nausea.

• Instruct patient to swallow extended-release tablets whole and not to chew, crush, or divide them.

• Inform patient that hallucinations may occur during ropinirole therapy.

• Advise patient that he may experience the urge to gamble, increased sexual urges, or other intense urges and the inability to control these urges.

• Inform patient (and caregiver, as appropriate) that drug can cause serious CNS reactions; tell him which ones to report. Recommend appropriate safety measures.

• Instruct patient to move slowly when sitting up or standing, to avoid dizziness from sudden blood pressure decrease.

Caution patient not to stop drug abruptly. Dosage must be tapered.

• Advise patient to report swelling of hands or feet.

• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, vision, and alertness.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

Requip

(rē′kwĭp′)
A trademark for the drug ropinirole hydrochloride.

Requip®

Ropinirole Pharmacology A 2nd-generation dopamine agonist for treating Parkinson's disease. See Parkinson's disease.

Requip

A brand name for ROPINIROLE.
References in periodicals archive ?
ReQuip is taken to alleviate the symptoms of the central nervous system disorder, which causes shaking.
While taking Requip, Jambart attempted suicide eight times and his risky sexual encounters resulted in him being raped.
Vicki had eight weeks off work and started taking ReQuip, a drug to control the symptoms and slow the condition.
In October 2004 his doctor prescribed an alternative dopamine agonist, Requip.
The approval is for multiple strengths of the drug, which is the generic version of GlaxoSmithKline Plc's Requip that is used to treat Parkinson's disease and primary restless leg syndrome.
Patients should 22 mg also tell their doctor 24 mg if they experience new or increased gambling, sexual, or other intense urges while taking Requip XL.
Anticipated Generic Availability Brand Name (generic name) Common Uses (2008) Tegretol XR Seizures January-March (carbamazepine extended-release) Fosamax and Fosamax Weekly Osteoporosis February (alendronate sodium) Requip (ropinirole Hcl) Parkinson's/Restless May Legs Syndrome Risperdal (risperidone) Mental/mood disorders June/July Dovonex (calcipotriene) Psoriasis July-September Cipro HC (ciprofloxacin/ External ear July-September hydrocortisone solution) infections Severent Diskus and Inhaler Asthma/chronic July-September (salmeterol) obstructive pulmonary disease Altace (ramipril) Cardiovascular October Paxil CR (paroxetine Anxiety, depression October hydrochloride) Imitrex (sumatriptan) Migraines To Be Determined Sources: LifeWise; Premera Blue Cross; University of Michigan; U.
Ropinirole, a non-ergoline dopamine agonist, is marketed as Requip by Glaxo-SmithKline Inc.
Fortunately, these conditions respond well to medications, such as, Requip and Mirapex (originally marketed for Parkinson's disease) and muscle relaxants.
In the regional portfolio, ahead of final year results due to be announced on Thursday, GlaxoSmithKline's drug Requip XL was again in the spotlight.
is a dopamine agonist that was first approved by the FDA for the treatment of Parkinson's disease in 1997, along with GlaxoSmithKline's similar drug Requip (ropinirole).